CLAIMS

1. A compound of formula I:



or a pharmaceutically acceptable salt thereof.

2. A medicament for use in the treatment of a respiratory tract disease, comprising the compound or the pharmaceutically acceptable salt of claim 1.

3. The medicament for use of claim 2, wherein the respiratory tract disease is rhinosinusitis.

4. The medicament for use of claim 2, wherein the respiratory tract disease is caused by an RNA-comprising virus.

5. The medicament for use of claim 4, wherein the virus is selected from the group consisting of rhinovirus, Coxsackie virus, respiratory syncytial virus, and influenza virus.

6. The medicament for use of claim 4 or 5, wherein the disease is exacerbations of asthma, chronic obstructive pulmonary disease, bronchitis and mucoviscidosis, which are caused by rhinovirus, influenza virus and/or respiratory syncytial virus.

7. A pharmaceutical composition for use in the treatment of a respiratory tract disease, comprising an effective amount of the compound or the pharmaceutically acceptable salt of claim 1, and a pharmaceutically acceptable carrier.

8. The pharmaceutical composition for use of claim 7, wherein the respiratory tract disease is rhinosinusitis.

9. The pharmaceutical composition for use of claim 7, wherein the respiratory tract disease is caused by an RNA-comprising virus.

10. The pharmaceutical composition for use of claim 9, wherein the virus is selected from the group consisting of rhinovirus, Coxsackie virus, respiratory syncytial virus, and influenza.

11. The pharmaceutical composition for use of claim 7, wherein the disease is exacerbations of asthma, chronic obstructive pulmonary disease, bronchitis and mucoviscidosis, which are caused by rhinovirus, influenza virus and/or respiratory syncytial virus.

12. Use of the compound or the pharmaceutically acceptable salt of claim 1 in the manufacture of a medicament for the treatment of a respiratory tract disease.

13. The use of claim 12, wherein the respiratory tract disease is rhinosinusitis.

14. The use of claim 12, wherein the respiratory tract disease is caused by an RNA-comprising virus.

15. The use of claim 14, wherein the virus is selected from the group consisting of rhinovirus, Coxsackie virus, respiratory syncytial virus, and influenza virus.

16. The use of claim 12, wherein the disease is exacerbations of asthma, chronic obstructive pulmonary disease, bronchitis and mucoviscidosis, which are caused by rhinovirus, influenza virus and/or respiratory syncytial virus.

17. A method for preparing a compound of formula



according to claim 1 or a pharmaceutically acceptable salt thereof, comprising heating of the compound of general formula II



wherein

m is 2;

each of R^a_1, R^b_1, R^c_1, R^d_1, R^e_1, R^f_1, R_2 is H;

R_3 is 

with a dehydrating agent in an organic solvent.

18. The method of claim 17, wherein the dehydrating agent and the organic solvent are acetic acid anhydride.

19. The method of claim 18, wherein the method is performed with addition of sodium acetate.